Flibanserin (Addyi) and Benzodiazepines: Interaction Risk, Mechanism, and Clinical Guidance

The core answer

Flibanserin and benzodiazepines are both centrally acting depressants, and combining them plausibly increases sedation, dizziness, and blood pressure lowering beyond what either drug produces alone. This risk is grounded in pharmacology and in the FDA label's general caution about CNS depressants, but the benzodiazepine-specific magnitude of that risk has not been established in a dedicated, published interaction study the way the flibanserin-alcohol interaction has. The safest working assumption for prescribers is to treat the combination as clinically meaningful but not absolutely prohibited, manage it with dose timing and monitoring, and reassess if sedation or hypotension appears.

Why this combination gets attention

Flibanserin was developed as an antidepressant candidate before being repurposed for hypoactive sexual desire disorder (HSDD). Its serotonergic and dopaminergic activity, primarily 5-HT1A agonism and 5-HT2A antagonism, produces dose-dependent sedation and blood pressure lowering as part of its known pharmacology, which is why the FDA restricted dosing to bedtime only rather than as a side effect that appears only occasionally.

The FDA approved flibanserin in 2015 alongside a Risk Evaluation and Mitigation Strategy (REMS) program built around CNS depression and alcohol interaction concerns. The current prescribing information should be consulted for the exact REMS elements in force, since FDA modified some REMS requirements after initial approval, and this article does not attempt to restate the current REMS mechanics precisely without checking the live label.

Benzodiazepines work through a different mechanism, potentiating GABA-A receptor chloride conductance, but the downstream clinical effect (sedation, reduced alertness, lowered blood pressure via reduced sympathetic tone) overlaps substantially with flibanserin's effects. Two drugs pushing the CNS toward depression through separate mechanisms is the classic setup for an additive, rather than synergistic-in-a-novel-way, interaction.

Mechanism: mostly pharmacodynamic, possibly some pharmacokinetic overlap

Pharmacodynamic overlap (established mechanism, not established magnitude). Flibanserin's serotonergic activity reduces cortical excitation and alertness. Benzodiazepines enhance GABA-A mediated inhibition throughout the cortex, brainstem, and spinal cord. Layering these mechanisms is expected to compound somnolence, psychomotor slowing, and blood pressure lowering. This is a well-accepted pharmacologic principle, but the specific size of the combined effect (how much more sedated, how much lower the blood pressure drops) has not been quantified in a public dedicated flibanserin-benzodiazepine interaction trial, as far as the sources reviewed for this article show.

Pharmacokinetic overlap (plausible, unquantified). Flibanserin is metabolized substantially by CYP3A4. Several commonly used benzodiazepines, including alprazolam and triazolam, are also CYP3A4 substrates. When two CYP3A4 substrates are combined, competition for the enzyme can, in principle, slow clearance and raise plasma levels of one or both drugs. The FDA label documents that strong CYP3A4 inhibitors (such as azole antifungals) meaningfully raise flibanserin exposure, which is why those drugs are contraindicated. Benzodiazepines are not strong CYP3A4 inhibitors in that same category, so a comparable magnitude of interaction should not be assumed. Lorazepam and oxazepam are cleared by glucuronidation rather than CYP3A4, which removes this specific pharmacokinetic concern for those two agents, though it does not remove the pharmacodynamic overlap described above.

Evidence boundary: what is established, plausible, and unproven

• Established: flibanserin causes dose-dependent sedation and can lower blood pressure; this is documented in FDA review and is the basis for bedtime-only dosing and REMS oversight. Benzodiazepines independently cause sedation and can lower blood pressure through reduced sympathetic tone. Flibanserin combined with alcohol, a different CNS depressant, produced a clinically significant hypotension and syncope signal in FDA-reviewed interaction testing, which is why alcohol is contraindicated.
• Plausible but not independently proven for benzodiazepines specifically: that combining flibanserin with a benzodiazepine produces additive sedation and hypotension of a magnitude comparable to the flibanserin-alcohol finding. This extrapolation is pharmacologically reasonable but has not, based on the sources reviewed here, been confirmed in a dedicated benzodiazepine interaction study.
• Not established: a specific numeric increase in sedation risk, a validated benzodiazepine dose-reduction schedule for co-administration with flibanserin, or a quantified difference in real-world outcomes between glucuronidated benzodiazepines and CYP3A4-metabolized ones when combined with flibanserin.
• Requires verification before clinical use: the current REMS requirements, the current label language on CNS depressants, and any benzodiazepine-specific guidance, since flibanserin's REMS program has been modified since its 2015 approval and the label should be checked at the time of prescribing.

Evidence-status interaction assessment

Monitoring if both drugs are clinically necessary

If a prescriber and patient decide the combination is warranted (for example, a patient with an anxiety disorder who cannot safely stop a benzodiazepine and also has HSDD), a reasonable monitoring plan includes:

• Orthostatic blood pressure checks at baseline and at early follow-up visits after starting the combination, since both drugs can lower blood pressure.
• Direct questioning about daytime sedation, dizziness, and near-fainting, especially in the first one to two weeks, since flibanserin is dosed to reach steady state within a few days.
• Fall-risk assessment, particularly in older patients or those on additional sedating medications.
• A specific conversation about driving and operating machinery if the patient reports any morning grogginess, since flibanserin is dosed at bedtime specifically to keep peak sedation during sleep.

Practical approaches used in practice (not FDA-validated protocols)

These are pragmatic strategies clinicians may consider; none of them has been validated in a dedicated interaction trial, and they do not eliminate the underlying pharmacodynamic risk.

• Separating dosing times, giving the benzodiazepine earlier in the evening and flibanserin at bedtime, so peak concentrations do not fully overlap. This may reduce peak additive sedation but does not remove the interaction.
• Using the lowest effective benzodiazepine dose, in coordination with the prescriber managing the anxiety or sleep disorder, rather than adjusting flibanserin, which is only available at one FDA-approved strength (100 mg).
• Considering a switch to a non-benzodiazepine anxiolytic (for example, buspirone) before starting flibanserin, where clinically appropriate, recognizing that buspirone's own serotonergic activity should be reviewed against flibanserin's mechanism by the prescriber.
• Avoiding benzodiazepine dose increases while on flibanserin without discussing it with the prescriber managing Addyi, since even modest changes shift the sedation and hypotension balance.

Benzodiazepines should never be stopped abruptly without medical supervision because of withdrawal seizure risk; any change in benzodiazepine therapy driven by a flibanserin prescription should go through a supervised taper plan if discontinuation is being considered.

Why the alcohol warning is relevant even though alcohol is not a benzodiazepine

Flibanserin carries a boxed warning and absolute contraindication with alcohol because FDA-reviewed interaction testing showed a clinically significant hypotension and syncope signal when the two were combined. Alcohol and benzodiazepines are pharmacologically related in that both potentiate GABA-A activity, so the directional concern (more sedation, more blood pressure lowering) is the same in kind, even though benzodiazepines have a wider therapeutic margin and more predictable pharmacokinetics than alcohol. This parallel supports caution with benzodiazepines; it does not mean the risk magnitude is identical, and readers should not assume a benzodiazepine-flibanserin combination carries the same event rate reported for the alcohol interaction without checking a benzodiazepine-specific source.

Populations that may carry added risk

• Hepatic impairment: flibanserin clearance depends on hepatic metabolism, and the label restricts use in moderate-to-severe hepatic impairment. Patients with any degree of liver disease who also take a benzodiazepine may have compounded clearance delays for both drugs; this combination warrants specific discussion with the prescriber and possibly hepatology input.
• Older reproductive-age patients: age-related changes in hepatic blood flow, enzyme activity, and orthostatic reflex all point toward increased sensitivity to combined sedative and hypotensive effects, though this has not been separately quantified for the flibanserin-benzodiazepine pair.
• Patients on additional CNS depressants (opioids, sedating antihistamines, muscle relaxants, other sleep aids): the risk framework here applies more broadly than just to benzodiazepines, and a full medication reconciliation is the more useful clinical step than focusing on benzodiazepines alone.

Alternatives worth discussing with a prescriber

• Bremelanotide (Vyleesi), an as-needed subcutaneous injection approved for HSDD, works through melanocortin receptors rather than serotonin pathways and does not carry the same CNS-depressant profile as flibanserin. It is not automatically free of all interaction concerns, and its own label should be checked for the individual patient.
• Testosterone therapy, used off-label for HSDD in premenopausal women, does not carry a CNS-depression profile, but off-label status, monitoring requirements, and the strength of the supporting evidence in premenopausal patients specifically should be discussed directly with the prescriber.
• Psychotherapy or sex therapy approaches for HSDD carry no drug interaction risk and can be used alongside either pharmacologic option, though response varies by individual and by therapy type, and specific response-rate figures should come from the therapy's own evidence base rather than being borrowed from an unrelated citation.
• Non-benzodiazepine anxiety treatment (buspirone, SSRIs where not contraindicated, cognitive behavioral therapy) may allow flibanserin to be used with less CNS-depressant load, but any SSRI or SNRI change should be checked against flibanserin's own contraindication list, since some strong CYP3A4-inhibiting antidepressants are contraindicated with flibanserin regardless of the benzodiazepine question.

What patients should know

• Take flibanserin at bedtime only, never during waking hours, regardless of when the benzodiazepine dose was taken.
• If morning drowsiness, dizziness, or lightheadedness occurs, avoid driving or operating machinery and contact the prescriber.
• Alcohol is not permitted while on flibanserin, and combining flibanserin, a benzodiazepine, and alcohol would compound the CNS-depressant load further.
• Report any fainting, near-fainting, or falls promptly.
• Do not increase a benzodiazepine dose without telling the clinician who prescribed flibanserin, since even a modest change shifts the risk balance.
• Seek urgent care for very slow or shallow breathing, unresponsiveness, or difficulty waking after taking both medications; these are signs of dangerous CNS depression, not routine sedation.

Bottom line

The flibanserin-benzodiazepine combination is not absolutely contraindicated, but it is not a routine pairing either. The clinically important question is not which specific benzodiazepine is "approved" alongside flibanserin, since no benzodiazepine carries a labeled clearance for this combination, but whether the prescriber has documented a benefit-risk assessment, counseled the patient on sedation and driving, and put a monitoring plan in place. Choosing a glucuronidated benzodiazepine (lorazepam, oxazepam) over a CYP3A4-metabolized one (alprazolam, triazolam, midazolam) may reduce the pharmacokinetic contribution to the interaction, but it does not remove the pharmacodynamic overlap that is the primary concern. Reassess the need for both drugs regularly, and consider bremelanotide as an alternative HSDD therapy if sedation becomes limiting.